NCT05376345 - BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

May 27, 2025

Study Completion Date

May 27, 2025

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

BIOLOGICAL

LCAR-BCDR cells product

Before treatment with LCAR-BCDR cells, subjects will receive a conditioning regimen

Trial Locations (6)

Beijing Gobroad Boren Hospital, Beijing

Zhejiang Provincial People's Hospital, Hangzhou

Shanghai Changzheng Hospital, Shanghai

Shanghai Fourth People's Hospital Affiliated to Tongji University, Shanghai

Institute of Hematology & Blood Diseases Hospital, Tianjin

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou